Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for SAB Biotherapeutics (SABSW) over the last 5 years, with Q3 2025 value amounting to $800764.0.

  • SAB Biotherapeutics' Share-based Compensation fell 2364.83% to $800764.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 3630.22%. This contributed to the annual value of $2.9 million for FY2024, which is 2421.11% down from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Share-based Compensation is $800764.0, which was down 2364.83% from $627198.0 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Share-based Compensation registered a high of $2.0 million during Q4 2023, and its lowest value of $349115.0 during Q1 2021.
  • For the 5-year period, SAB Biotherapeutics' Share-based Compensation averaged around $729113.7, with its median value being $628540.0 (2022).
  • As far as peak fluctuations go, SAB Biotherapeutics' Share-based Compensation skyrocketed by 21735.85% in 2023, and later tumbled by 6620.41% in 2024.
  • SAB Biotherapeutics' Share-based Compensation (Quarter) stood at $651472.0 in 2021, then decreased by 3.52% to $628540.0 in 2022, then surged by 217.36% to $2.0 million in 2023, then plummeted by 66.2% to $674135.0 in 2024, then rose by 18.78% to $800764.0 in 2025.
  • Its Share-based Compensation stands at $800764.0 for Q3 2025, versus $627198.0 for Q2 2025 and $612951.0 for Q1 2025.